Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun;14(4):1361-1369.
doi: 10.1016/j.nano.2018.03.008. Epub 2018 Apr 9.

Inhalable gadofullerenol/[70] Fullerenol as High-Efficiency ROS Scavengers for Pulmonary Fibrosis Therapy

Affiliations

Inhalable gadofullerenol/[70] Fullerenol as High-Efficiency ROS Scavengers for Pulmonary Fibrosis Therapy

Yue Zhou et al. Nanomedicine. .

Abstract

Pulmonary fibrosis has become a fatal disease for its high incidence and few effective drugs available in clinic. In this study, gadofullerenol (GF-OH) and [70] fullerenol (C70-OH) nanoparticles (NPs) prepared by a one-pot reaction were designed as nanomedicines to treat this fatal disease. It was revealed that the inhalation of gadofullerenols and [70] fullerenols substantially alleviates the collagen deposition induced by acute lung injury. Based on detailed studies of oxidative stress parameters and transforming growth factor-β1 (TGF-β1), we demonstrated they owned the antioxidant and anti-inflammatory functions for the modulation of ROS-mediated inflammation process. Thus the therapeutic effect may be associated with synergistic mechanism of scavenging free radicals and indirectly modulating TGF-β1 expression. Moreover, GF-OH NPs were observed to show the superiority to C70-OH NPs both in vitro and in vivo due to the structural distinction. These results suggest the inhalable fullerenols are highly potential for clinical therapy of pulmonary fibrosis.

Keywords: Gadofullerenol; Inhalant; Pulmonary fibrosis; ROS scavenger; [70] Fullerenol.

Similar articles

See all similar articles

Cited by 1 article

Publication types

Feedback